vadadustat
Jump to navigation
Jump to search
Indications
- anemia due to chronic kidney disease
Dosage
Mechanism of action
- prolyl hydroxylase inhibitor
- stabilizes hypoxia-inducible factor
- stimulates erythropoietin & erythrocyte production
More general terms
References
- ↑ Chertow GM, Pergola PE, Farag YMK Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med 2021; 384:1589-1600. April 29 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33913637 https://www.nejm.org/doi/full/10.1056/NEJMoa2035938